PD

Peter Dilaura

Strategic Advisor at Sonoma Biotherapeutics

San Francisco, California

Overview 

Peter DiLaura is the President and CEO of Initial Therapeutics in San Francisco, California. With a background in biotechnology and life sciences, he has held leadership roles at companies like Second Genome, Inc., and has expertise in strategic planning, business development, and commercialization. Highlights of Peter's career include serving as President & CEO at Second Genome, Inc., and currently leading Initial Therapeutics as President and CEO, demonstrating his strong track record in executive leadership within the biotechnology industry. His experience in strategic planning, business development, and commercialization make him a valuable asset in driving the success of innovative life science companies.

Work Experience 

IT

Initial Therapeutics

  • President and CEO

    2024 - Current

Initial Therapeutics is a developer of small-molecule medicines designed to prevent pathogenic protein synthesis.

Raised $78,800,000.00 from Apple Tree Partners.

initialtx.com
SB

Sonoma Biotherapeutics

  • Strategic Advisor

    2024

  • Chief Business and Strategy Officer

    2020 - 2024

    Member of the Executive Team, responsible for all elements of company operations and strategy, including financing, corporate development and partnering, financial operations, program and portfolio management, legal, and HR. - Led financing efforts, including $265M Series B financing - Led corporate development efforts, including principal sourcing and negotiation of multi-indication discovery, development, and commercialization collaboration with Regeneron, with $75M upfront, $45M in early milestones, and 50/50 cost and profit sharing structure - Built and managed Finance, Legal, HR, and Program Management functions

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Raised $365,000,000.00 from Regeneron.

sonomabio.com
CB

Character Biosciences

  • Member Board of Directors

    2020

TR

Third Rock Ventures

  • Entrepreneur In Residence

    2018 - 2020

    Led and supported incubation efforts for multiple early company concepts.

DD

Dementia Discovery Fund

  • Strategic Advisor

    2017 - 2019

T

Takeda

  • Advisor

    2017 - 2017

SG

Second Genome, Inc.

  • President & CEO

    2010 - 2016

    CEO and Director of Second Genome, a South San Francisco biotechnology company developing novel drugs from microbiome science. Led the company from an early team of founders to 30 employees.

Ingenuity Systems

  • Senior Vice President

    2001 - 2010

    Commercial roles with increasing responsibility at Ingenuity Systems, a Bay Area systems biology company.

Ventro/Chemdex

  • Vice President, Business Development

    1999 - 2001

    Responsible for corporate strategy, business development, and marketing activities for publicly traded life sciences e-commerce pioneer.

The Wilkerson Group (an IBM Company)

  • Consultant

    1995 - 1999

    Strategic consulting to clients in the pharmaceutical, biotech, medical device and diagnostic industries, focused on opportunity assessment, merger and acquisition advisory, and strategic planning.

Education 

Articles About Peter

Relevant Websites